ATAI vs DFTX
ATAI: A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments. DFTX: Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and autism.
Side-by-side fundamentals
| Metric | ATAI | DFTX | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $7.25 | $45.15 | |
| Market cap as of 2026-08-11 | $2.7B | $6.1B | |
| PEG as of 2026-08-11 | n/a | -0.10 | |
| Net margin as of 2026-08-11 | -19019.4% | n/a | |
| Operating margin as of 2026-08-11 | -18569.1% | n/a | |
| ROE as of 2026-08-11 | -366.5% | -85.2% | DFTX higher |
| ROA as of 2026-08-11 | -269.0% | -64.6% | DFTX higher |
| Debt / equity as of 2026-08-11 | 0.00 | 0.04 | ATAI lower |
| Revenue growth (YoY) as of 2026-08-11 | +86.7% | n/a | |
| Beta as of 2026-08-11 | 1.58 | 2.24 | |
| 1-year return as of 2026-08-10 close | +75.5% | +358.4% | DFTX higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.